Literature DB >> 18350592

Novel therapeutic approaches for hepatocellulcar carcinoma: fact and fiction.

Yuan-Yuan Zhang, Harry-Hua-Xiang Xia.   

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and accounts for 80%-90% of this class of malignancy. So far, understanding of its pathogenesis and effective therapeutic methods are rather limited. In this issue, 11 invited review articles are published to address current advance of underlying molecular mechanisms for the development of HCC, and novel therapeutic approaches for HCC. This series of review articles provide an in-depth unders-tanding of HCC that has led to or may lead to the development of novel therapies for HCC.

Entities:  

Mesh:

Year:  2008        PMID: 18350592      PMCID: PMC2695901          DOI: 10.3748/wjg.14.1641

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  14 in total

Review 1.  Tumor suppressor and hepatocellular carcinoma.

Authors:  Juliette Martin; Jean-Francois Dufour
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

2.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

Review 3.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

Authors:  Hashem B El-Serag; K Lenhard Rudolph
Journal:  Gastroenterology       Date:  2007-06       Impact factor: 22.682

Review 4.  Is human hepatocellular carcinoma a hormone-responsive tumor?

Authors:  Massimo Di Maio; Bruno Daniele; Sandro Pignata; Ciro Gallo; Ermelinda De Maio; Alessandro Morabito; Maria-Carmela Piccirillo; Francesco Perrone
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 5.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 6.  Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma.

Authors:  Patrick Arbuthnot; Liam-Jed Thompson
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 7.  Molecular mechanism underlying the functional loss of cyclindependent kinase inhibitors p16 and p27 in hepatocellular carcinoma.

Authors:  Yasunobu Matsuda
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 8.  Current role of ultrasound for the management of hepatocellular carcinoma.

Authors:  Hitoshi Maruyama; Masaharu Yoshikawa; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 9.  Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.

Authors:  Kai Breuhahn; Peter Schirmacher
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 10.  Strategies for the management of hepatocellular carcinoma.

Authors:  Myron Schwartz; Sasan Roayaie; Manousos Konstadoulakis
Journal:  Nat Clin Pract Oncol       Date:  2007-07
View more
  5 in total

1.  VEGF is essential for the growth and migration of human hepatocellular carcinoma cells.

Authors:  Lei Zhang; Jia-Ning Wang; Jun-Ming Tang; Xia Kong; Jian-Ye Yang; Fei Zheng; Ling-Yun Guo; Yong-Zhang Huang; Li Zhang; Lin Tian; Shu-Fen Cao; Chang-Hai Tuo; Hong-Li Guo; Shi-You Chen
Journal:  Mol Biol Rep       Date:  2011-12-10       Impact factor: 2.316

2.  Nanosized As2O3/Fe2O3 complexes combined with magnetic fluid hyperthermia selectively target liver cancer cells.

Authors:  Zi-Yu Wang; Jian Song; Dong-Sheng Zhang
Journal:  World J Gastroenterol       Date:  2009-06-28       Impact factor: 5.742

3.  Meta-analysis of surgical resection and radiofrequency ablation for early hepatocellular carcinoma.

Authors:  Gang Xu; Fu-Zhen Qi; Jian-Huai Zhang; Guo-Feng Cheng; Yong Cai; Yi Miao
Journal:  World J Surg Oncol       Date:  2012-08-16       Impact factor: 2.754

Review 4.  Comparative Efficacy of Interventional Therapies for Early-stage Hepatocellular Carcinoma: A PRISMA-compliant Systematic Review and Network Meta-analysis.

Authors:  Tian Lan; Lei Chang; M N Rahmathullah; Long Wu; Yu-Feng Yuan
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 5.  Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis.

Authors:  Chenyang Duan; Mengying Liu; Zhuohang Zhang; Kuansheng Ma; Ping Bie
Journal:  World J Surg Oncol       Date:  2013-08-13       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.